New partnership between Genome Canada and adMare BioInnovations to drive commercialization of genomics solutions in healthcare
Ottawa, ON—In celebration of Global Biotech Week, today at the national BIONATION 2022 conference, the leaders of Genome Canada and adMare BioInnovations announced a new strategic partnership to support the translation of genomics research into commercialization opportunities in healthcare.
Genomics-enabled precision health tools are speeding up diagnoses and improving health outcomes and disease management for Canadians. They are critical to the important shift from a disease-oriented healthcare system to one that is more precise, personalized, predictive, preventative, and cost effective. Biological innovation has enormous potential to drive economic growth. McKinsey Global Institute estimates the direct annual global impact of biological applications for healthcare at US$0.5 to $1.3 trillion over the 2030-40 period.
By leveraging the individual strengths, networks, programs, and expertise of Genome Canada and adMare, the goal of the new memorandum of understanding signed today is to engage in concrete joint activities that will strengthen the university-to-company innovation pipeline in Canada’s life sciences ecosystem—accelerating and maximizing impact in the healthcare and pharmaceutical sectors.
“This is a very exciting collaboration with Genome Canada,” says Gordon C. McCauley. “Together, we will translate strong academic research into robust companies, bring innovation from bench to bedside faster, foster the development of novel intellectual property here in Canada, creating a sustainable Canadian biotech ecosystem with high-quality jobs.”
This agreement is an excellent example of innovative, value-add collaboration between two national leaders in the life sciences and genomics ecosystem in Canada. adMare will work together with Genome Canada to identify viable commercial projects and support their development into sustainable enterprises.
The initial focus will be to connect researchers supported by Genome Canada’s Genomics Applications Partnership Program (GAPP) with adMare’s resources and expertise in industrial drug development, commercial innovation and business development. GAPP invests in downstream research and development projects that address real-world problems identified by industry, government, not-for-profits, and other “receptors” of genomics knowledge and technologies.
“Genome Canada is thrilled about our new impact-oriented partnership with adMare,” says Dr. Annan. “It will allow us to build a robust innovation pipeline in healthcare diagnostics and therapeutics, connecting our investments and project partners with adMare’s commercial assessment and financial support systems.”